Peter D. Haytaian - 03 Mar 2025 Form 4 Insider Report for Elevance Health, Inc. (ELV)

Reporting relationship: EVP & Pres Carelon & CarelonRx
Issuer ticker: ELV
Reported as of: 03 Mar 2025
Net transaction value: -$902,136
SEC form: 4
Accepted by SEC: 05 Mar 2025, 16:48:33 UTC
Prior SEC filing: 05 Nov 2024
Next SEC filing: 04 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Kathleen S. Kiefer, Attorney in fact

Key filing fact

Peter D. Haytaian filed Form 4 for Elevance Health, Inc. (ELV) on 05 Mar 2025.

Key facts

This page summarizes Peter D. Haytaian's Form 4 filing for Elevance Health, Inc. (ELV).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Mar 2025, 16:48.

Change

Previous filing in this sequence was filed on 05 Nov 2024.
Current net transaction value: -$902,136.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ELV transaction

Common Stock

Tax liability

Transaction value: $902,136
Shares: -2,281
Change %: -11%
Price: $395.50
Shares after: 18,756
Date: 03 Mar 2025
Ownership: Direct
Footnotes: F1

ELV transaction

Common Stock

Award

Transaction value: $0
Shares: +3,035
Change %: +16%
Price: $0.000000
Shares after: 21,791
Date: 03 Mar 2025
Ownership: Direct
Footnotes: F2

ELV transaction

Common Stock

Award

Transaction value: $0
Shares: +4,213
Change %: +19%
Price: $0.000000
Shares after: 26,004
Date: 03 Mar 2025
Ownership: Direct
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELV transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +11,549
Change %
Price: $0.000000
Shares after: 11,549
Date: 03 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,549
Exercise price: $395.50
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK.

Footnote F2

Represents restricted share units. Restrictions lapse as follows: 1,011 shares on 3/3/2026, and 1,012 shares each on 3/3/2027 and 3/3/2028.

Footnote F3

Represents performance based restricted share units. Restrictions lapse on 3/3/2025.

Footnote F4

The option represents a right to purchase a total of 11,549 shares, and is exercisable in three annual installments, with one installment of 3,849 shares and two installments of 3,850 shares each, beginning on 3/3/2026, which is the one-year anniversary of the option grant date.